Chemoprevention of Gastric Carcinogenesis

Research Group
Gastrointestinal and Other Cancers
Sponsor
Vanderbilt-Ingram Cancer Center
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02794428
A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO) in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk regions of Latin America.
Intervention
Eflornithine, Eflornithine placebo
Condition
Gastric Cancer, Gastric Intestinal Metaplasia
Investigators
Doug Morgan, MD, Keith Wilson, MD

See list of participating sites